{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:21:56Z","timestamp":1790259716440,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T00:00:00Z","timestamp":1264550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s15010-009-9179-z","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T13:37:50Z","timestamp":1264599470000},"page":"3-11","source":"Crossref","is-referenced-by-count":54,"title":["Hepatotoxicity of Antibacterials: Pathomechanisms and Clinical Data"],"prefix":"10.1007","volume":"38","author":[{"given":"J. M.","family":"Leitner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Thalhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,27]]},"reference":[{"key":"9179_CR1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrd2677","volume":"7","author":"B. Hughes","year":"2008","unstructured":"Hughes B: Industry concern over EU hepatotoxicity guidance. Nat Rev Drug Discov 2008; 7: 719.","journal-title":"Nat Rev Drug Discov"},{"key":"9179_CR2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-004-0888-z","volume":"61","author":"Y. Meier","year":"2005","unstructured":"Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K: Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135\u2013143.","journal-title":"Eur J Clin Pharmacol"},{"key":"9179_CR3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1021\/mp060133c","volume":"4","author":"H.U. Marschall","year":"2007","unstructured":"Marschall HU, Wagner M, Zollner G, Trauner M: Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol Pharm 2007; 4: 895\u2013910.","journal-title":"Mol Pharm"},{"key":"9179_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1089-3261(05)70097-0","volume":"4","author":"H.J. Zimmerman","year":"2000","unstructured":"Zimmerman HJ: Drug-induced liver disease. Clin Liver Dis 2000; 4: 73\u201396vi.","journal-title":"Clin Liver Dis"},{"key":"9179_CR5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cld.2007.06.009","volume":"11","author":"J.E. Polson","year":"2007","unstructured":"Polson JE: Hepatotoxicity due to antibiotics. Clin Liver Dis 2007; 11: 549\u2013561vi.","journal-title":"Clin Liver Dis"},{"key":"9179_CR6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","volume":"99","author":"M.A. Steele","year":"1991","unstructured":"Steele MA, Burk RF, DesPrez RM: Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465\u2013471.","journal-title":"Chest"},{"key":"9179_CR7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"J.J. Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935\u2013952.","journal-title":"Am J Respir Crit Care Med"},{"key":"9179_CR8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","volume":"11","author":"W.W. Yew","year":"2006","unstructured":"Yew WW, Leung CC: Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699\u2013707.","journal-title":"Respirology"},{"key":"9179_CR9","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1097\/01.mcg.0000155551.37266.26","volume":"39","author":"M. Trauner","year":"2005","unstructured":"Trauner M, Wagner M, Fickert P, Zollner G: Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 2005; 39: S111\u2013S124.","journal-title":"J Clin Gastroenterol"},{"key":"9179_CR10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2009.05.012","volume":"51","author":"M. Wagner","year":"2009","unstructured":"Wagner M, Zollner G, Trauner M: New molecular insights into the mechanisms of cholestasis. J Hepatol 2009; 51: 565\u2013580.","journal-title":"J Hepatol"},{"key":"9179_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2007.11.010","volume":"12","author":"G. Zollner","year":"2008","unstructured":"Zollner G, Trauner M: Mechanisms of cholestasis. Clin Liver Dis 2008; 12: 1\u201326vii.","journal-title":"Clin Liver Dis"},{"key":"9179_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cld.2007.11.002","volume":"12","author":"M. Fuchs","year":"2008","unstructured":"Fuchs M, Sanyal AJ: Sepsis and cholestasis. Clin Liver Dis 2008; 12: 151\u2013172ix.","journal-title":"Clin Liver Dis"},{"key":"9179_CR13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1089-3261(03)00021-7","volume":"7","author":"M. Thiim","year":"2003","unstructured":"Thiim M, Friedman LS: Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003; 7: 381\u2013399vi\u2013vii.","journal-title":"Clin Liver Dis"},{"key":"9179_CR14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","volume":"349","author":"W.M. Lee","year":"2003","unstructured":"Lee WM: Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474\u2013485.","journal-title":"N Engl J Med"},{"key":"9179_CR15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/hep.21095","volume":"43","author":"P.B. Watkins","year":"2006","unstructured":"Watkins PB, Seeff LB: Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618\u2013631.","journal-title":"Hepatology"},{"key":"9179_CR16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","volume":"42","author":"E. Bj\u00f6rnsson","year":"2005","unstructured":"Bj\u00f6rnsson E, Olsson R: Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481\u2013489.","journal-title":"Hepatology"},{"key":"9179_CR17","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","volume":"135","author":"N. Chalasani","year":"2008","unstructured":"Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J: Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924\u20131934, 1934.e1-4.","journal-title":"Gastroenterology"},{"key":"9179_CR18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","volume":"129","author":"R.J. Andrade","year":"2005","unstructured":"Andrade RJ, Lucena MI, Fern\u00e1ndez MC, Pelaez G, Pachkoria K, Garc\u00eda-Ruiz E, Garc\u00eda-Mu\u00f1oz B, Gonz\u00e1lez-Grande R, Pizarro A, Dur\u00e1n JA, Jim\u00e9nez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmer\u00f3n J, Martin-Vivaldi R: Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512\u2013521.","journal-title":"Gastroenterology"},{"key":"9179_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5414\/CPP41231","volume":"41","author":"M. M\u00fcller","year":"2003","unstructured":"M\u00fcller M: Pharmacogenomics and drug response. Int J Clin Pharmacol Ther 2003; 41: 231\u2013240.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9179_CR20","doi-asserted-by":"crossref","first-page":"12063","DOI":"10.1074\/jbc.271.20.12063","volume":"271","author":"S.S. Lee","year":"1996","unstructured":"Lee SS, Buters JT, Pineau T, Fern\u00e1ndez-Salguero P, Gonz\u00e1lez FJ: Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996; 271: 12063\u201312067.","journal-title":"J Biol Chem"},{"key":"9179_CR21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","volume":"37","author":"Y.S. Huang","year":"2003","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924\u2013930.","journal-title":"Hepatology"},{"key":"9179_CR22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","volume":"35","author":"Y.S. Huang","year":"2002","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883\u2013889.","journal-title":"Hepatology"},{"key":"9179_CR23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","volume":"84","author":"J.R. Mitchell","year":"1976","unstructured":"Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD: Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84: 181\u2013192.","journal-title":"Ann Intern Med"},{"key":"9179_CR24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/toxsci\/59.1.169","volume":"59","author":"A. Enomoto","year":"2001","unstructured":"Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O\u2019Connor T, Harada T, Yamamoto M: High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001; 59: 169\u2013177.","journal-title":"Toxicol Sci"},{"key":"9179_CR25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.47.5.717","volume":"47","author":"J. O\u2019Donohue","year":"2000","unstructured":"O\u2019Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR: Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47: 717\u2013720.","journal-title":"Gut"},{"key":"9179_CR26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S. Mallal","year":"2002","unstructured":"Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727\u2013732.","journal-title":"Lancet"},{"key":"9179_CR27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.1840080513","volume":"8","author":"E. Fr\u00e9neaux","year":"1988","unstructured":"Fr\u00e9neaux E, Labbe G, Letteron P, The Le Dinh, Degott C, Gen\u00e8ve J, Larrey D, Pessayre D: Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988; 8: 1056\u20131062.","journal-title":"Hepatology"},{"key":"9179_CR28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0002-9610(67)90308-X","volume":"113","author":"R.L. Peters","year":"1967","unstructured":"Peters RL, Edmondson HA, Mikkelsen WP, Tatter D: Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases. Am J Surg 1967; 113: 622\u2013632.","journal-title":"Am J Surg"},{"key":"9179_CR29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJM196311072691903","volume":"269","author":"J.C. Schultz","year":"1963","unstructured":"Schultz JC, Adamson JS Jr, Workman WW, Norman TD: Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963; 269: 999\u20131004.","journal-title":"N Engl J Med"},{"key":"9179_CR30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/00365529709007690","volume":"32","author":"E. Bj\u00f6rnsson","year":"1997","unstructured":"Bj\u00f6rnsson E, Lindberg J, Olsson R: Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol 1997; 32: 390\u2013395.","journal-title":"Scand J Gastroenterol"},{"key":"9179_CR31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.7326\/0003-4819-119-7_Part_1-199310010-00005","volume":"119","author":"J.L. Carson","year":"1993","unstructured":"Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, Das K: Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119: 576\u2013583.","journal-title":"Ann Intern Med"},{"key":"9179_CR32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/bmj.312.7024.169","volume":"312","author":"A. Gough","year":"1996","unstructured":"Gough A, Chapman S, Wagstaff K, Emery P, Elias E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312: 169\u2013172.","journal-title":"BMJ"},{"key":"9179_CR33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1309\/KV2J-VX6Q-L95V-VDE4","volume":"114","author":"N.S. Goldstein","year":"2000","unstructured":"Goldstein NS, Bayati N, Silverman AL, Gordon SC: Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000; 114: 591\u2013598.","journal-title":"Am J Clin Pathol"},{"key":"9179_CR34","first-page":"1873","volume":"25","author":"J.P. Boudreaux","year":"1993","unstructured":"Boudreaux JP, Hayes DH, Mizrahi S, Hussey J, Regenstein F, Balart L: Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proc 1993; 25: 1873.","journal-title":"Transplant Proc"},{"key":"9179_CR35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1572-0241.2000.t01-1-01809.x","volume":"95","author":"T. Pohle","year":"2000","unstructured":"Pohle T, Menzel J, Domschke W: Minocycline and fulminant hepatic failure necessitating liver transplantation. Am J Gastroenterol 2000; 95: 560\u2013561.","journal-title":"Am J Gastroenterol"},{"key":"9179_CR36","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1007\/s10620-006-9550-1","volume":"52","author":"J.E. Losanoff","year":"2007","unstructured":"Losanoff JE, Holder-Murray JM, Ahmed EB, Cochrane AB, Testa G, Millis JM: Minocycline toxicity requiring liver transplant. Dig Dis Sci 2007; 52: 3242\u20133244.","journal-title":"Dig Dis Sci"},{"key":"9179_CR37","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/106002808501900706","volume":"19","author":"P.F. D\u2019Arcy","year":"1985","unstructured":"D\u2019Arcy PF: Nitrofurantoin. Drug Intell Clin Pharm 1985; 19: 540\u2013547.","journal-title":"Drug Intell Clin Pharm"},{"key":"9179_CR38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJM196710122771503","volume":"277","author":"C.A. Dujovne","year":"1967","unstructured":"Dujovne CA, Chan CH, Zimmerman HJ: Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med 1967; 277: 785\u2013788.","journal-title":"N Engl J Med"},{"key":"9179_CR39","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.5858\/2000-124-1800-AFHFIA","volume":"124","author":"M.J. Ilario","year":"2000","unstructured":"Ilario MJ, Ruiz JE, Axiotis CA: Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim-sulfamethoxazole. Arch Pathol Lab Med 2000; 124: 1800\u20131803.","journal-title":"Arch Pathol Lab Med"},{"key":"9179_CR40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1665-2681(19)31956-8","volume":"6","author":"G. Kouklakis","year":"2007","unstructured":"Kouklakis G, Mpoumponaris A, Zezos P, Moschos J, Koulaouzidis A, Nakos A, Pehlivanidis A, Iosiphidis M, Molyvas E, Nikolaidis N: Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. Ann Hepatol 2007; 6: 63\u201365.","journal-title":"Ann Hepatol"},{"key":"9179_CR41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-102-5-722_1","volume":"102","author":"H.P. Lazar","year":"1985","unstructured":"Lazar HP, Murphy RL, Phair JP: Fansidar and hepatic granulomas. Ann Intern Med 1985; 102: 722.","journal-title":"Ann Intern Med"},{"key":"9179_CR42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-106-3-393","volume":"106","author":"B.J. Zitelli","year":"1987","unstructured":"Zitelli BJ, Alexander J, Taylor S, Miller KD, Howrie DL, Kuritsky JN, Perez TH, Van Thiel DH: Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann Intern Med 1987; 106: 393\u2013395.","journal-title":"Ann Intern Med"},{"key":"9179_CR43","first-page":"361","volume":"87","author":"B.G. Junghanss","year":"1998","unstructured":"Junghanss BG: Increase in transaminases in HIV infection. Toxic liver cell damage with trimethoprim\/sulfamethoxazole administration in HIV infection. Praxis (Bern 1994) 1998; 87: 361\u2013362.","journal-title":"Praxis (Bern 1994)"},{"key":"9179_CR44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(00)00367-3","volume":"109","author":"C. Wenisch","year":"2000","unstructured":"Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka E: Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med 2000; 109: 78.","journal-title":"Am J Med"},{"issue":"[Suppl2]","key":"9179_CR45","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0924-8579(98)00068-5","volume":"12","author":"K. Christiansen","year":"1999","unstructured":"Christiansen K: Fusidic acid adverse drug reactions. Int J Antimicrob Agents 1999; 12: [Suppl 2] S3\u2013S9.","journal-title":"Int J Antimicrob Agents"},{"key":"9179_CR46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0006-2952(02)01015-8","volume":"64","author":"K.A. Bode","year":"2002","unstructured":"Bode KA, Donner MG, Leier I, Keppler D: Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol 2002; 64: 151\u2013158.","journal-title":"Biochem Pharmacol"},{"key":"9179_CR47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","volume":"5","author":"E.J. Forget","year":"2006","unstructured":"Forget EJ, Menzies D: Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5: 231\u2013249.","journal-title":"Expert Opin Drug Saf"},{"key":"9179_CR48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-75-4-643","volume":"75","author":"D.L. Brummer","year":"1971","unstructured":"Brummer DL: Isoniazid and liver disease. Ann Intern Med 1971; 75: 643\u2013644.","journal-title":"Ann Intern Med"},{"key":"9179_CR49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2008-1040725","volume":"1","author":"W.C. Maddrey","year":"1981","unstructured":"Maddrey WC: Isoniazid-induced liver disease. Semin Liver Dis 1981; 1: 129\u2013133.","journal-title":"Semin Liver Dis"},{"key":"9179_CR50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cld.2009.02.008","volume":"13","author":"A.J. Pugh","year":"2009","unstructured":"Pugh AJ, Barve AJ, Falkner K, Patel M, McClain CJ: Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis 2009; 13: 277\u2013294.","journal-title":"Clin Liver Dis"},{"key":"9179_CR51","first-page":"735","volume":"52","author":"Centers for Disease ControlPrevention","year":"2003","unstructured":"Centers for Disease Control and Prevention (CDC):, American Thoracic Society: Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 735\u2013739.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9179_CR52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00004836-199706000-00019","volume":"24","author":"B. Knobel","year":"1997","unstructured":"Knobel B, Buyanowsky G, Dan M, Zaidel L: Pyrazinamide-induced granulomatous hepatitis. J Clin Gastroenterol 1997; 24: 264\u2013266.","journal-title":"J Clin Gastroenterol"},{"key":"9179_CR53","doi-asserted-by":"crossref","first-page":"600","DOI":"10.5694\/j.1326-5377.1993.tb137625.x","volume":"158","author":"L.E. Derby","year":"1993","unstructured":"Derby LE, Jick H, Henry DA, Dean AD: Erythromycin-associated cholestatic hepatitis. Med J Aust 1993; 158: 600\u2013602.","journal-title":"Med J Aust"},{"key":"9179_CR54","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/infdis\/119.3.300","volume":"119","author":"P. Braun","year":"1969","unstructured":"Braun P: Hepatotoxicity of erythromycin. J Infect Dis 1969; 119: 300\u2013306.","journal-title":"J Infect Dis"},{"key":"9179_CR55","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1023\/A:1020170807742","volume":"47","author":"S. Chandrupatla","year":"2002","unstructured":"Chandrupatla S, Demetris AJ, Rabinovitz M: Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002; 47: 2186\u20132188.","journal-title":"Dig Dis Sci"},{"key":"9179_CR56","first-page":"489","volume":"97","author":"K. Christopher","year":"2002","unstructured":"Christopher K, Hyatt PA, Horkan C, Yodice PC: Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol 2002; 97: 489\u2013490.","journal-title":"Am J Gastroenterol"},{"key":"9179_CR57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.22620","volume":"49","author":"A.D. Brinker","year":"2009","unstructured":"Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB: Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009; 49: 250\u2013257.","journal-title":"Hepatology"},{"key":"9179_CR58","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMp078032","volume":"356","author":"D.B. Ross","year":"2007","unstructured":"Ross DB: The FDA and the case of Ketek. N Engl J Med 2007; 356: 1601\u20131604.","journal-title":"N Engl J Med"},{"key":"9179_CR59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"V.J. Navarro","year":"2006","unstructured":"Navarro VJ, Senior JR: Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731\u2013739.","journal-title":"N Engl J Med"},{"key":"9179_CR60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.meg.0000250581.77865.68","volume":"19","author":"S.H. Hussaini","year":"2007","unstructured":"Hussaini SH, O\u2019Brien CS, Despott EJ, Dalton HR: Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 2007; 19: 15\u201320.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9179_CR61","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s10620-005-2938-5","volume":"50","author":"R.J. Fontana","year":"2005","unstructured":"Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM: Acute liver failure due to amoxicillin and amoxicillin\/clavulanate. Dig Dis Sci 2005; 50: 1785\u20131790.","journal-title":"Dig Dis Sci"},{"key":"9179_CR62","first-page":"139","volume":"6","author":"U. Gresser","year":"2001","unstructured":"Gresser U: Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature. Eur J Med Res 2001; 6: 139\u2013149.","journal-title":"Eur J Med Res"},{"key":"9179_CR63","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/archinte.156.12.1327","volume":"156","author":"L.A. Garc\u00eda Rodr\u00edguez","year":"1996","unstructured":"Garc\u00eda Rodr\u00edguez LA, Stricker BH, Zimmerman HJ: Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156: 1327\u20131332.","journal-title":"Arch Intern Med"},{"key":"9179_CR64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/dkm111","volume":"60","author":"F. Salvo","year":"2007","unstructured":"Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O, Motola D, Dusi G, Caputi AP: Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007; 60: 121\u2013126.","journal-title":"J Antimicrob Chemother"},{"key":"9179_CR65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","volume":"26","author":"R. Leone","year":"2003","unstructured":"Leone R, Venegoni M, Motola D, Moretti U, Piazzetta V, Cocci A, Resi D, Mozzo F, Velo G, Burzilleri L, Montanaro N, Conforti A: Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Saf 2003; 26: 109\u2013120.","journal-title":"Drug Saf"},{"issue":"[Suppl3]","key":"9179_CR66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000057838","volume":"47","author":"E. Rubinstein","year":"2001","unstructured":"Rubinstein E: History of quinolones and their side effects. Chemotherapy 2001; 47: [Suppl 3] 3\u20138, discussion 44-48.","journal-title":"Chemotherapy"},{"key":"9179_CR67","unstructured":"Drug Committee of the German Medical Association: hepatotoxicity of fluoroquinolones. Deutsches \u00c4rzteblatt 2002; A 3490."},{"key":"9179_CR68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(08)70002-1","volume":"8","author":"D.M. Shlaes","year":"2008","unstructured":"Shlaes DM, Moellering RC: Telithromycin and the FDA: implications for the future. Lancet Infect Dis 2008; 8: 83\u201385.","journal-title":"Lancet Infect Dis"},{"key":"9179_CR69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00002018-200932050-00001","volume":"32","author":"F. Bambeke Van","year":"2009","unstructured":"Van Bambeke F, Tulkens PM: Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359\u2013378.","journal-title":"Drug Saf"},{"key":"9179_CR70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00228-006-0222-z","volume":"63","author":"D. Motola","year":"2007","unstructured":"Motola D, Vargiu A, Leone R, Cocci A, Salvo F, Ros B, Meneghelli I, Venegoni M, Cutroneo PM, Vaccheri A, Velo G, Montanaro N: Hepatic adverse drug reactions: a case\/non-case study in Italy. Eur J Clin Pharmacol 2007; 63: 73\u201379.","journal-title":"Eur J Clin Pharmacol"},{"key":"9179_CR71","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5694\/j.1326-5377.1993.tb137624.x","volume":"158","author":"L.E. Derby","year":"1993","unstructured":"Derby LE, Jick H, Henry DA, Dean AD: Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 158: 596\u2013600.","journal-title":"Med J Aust"},{"key":"9179_CR72","first-page":"35","volume":"56","author":"C. Carbon","year":"2001","unstructured":"Carbon C: Levofloxacin adverse effects, data from clinical trials and pharmacovigilance. Therapie 2001; 56: 35\u201340.","journal-title":"Therapie"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-009-9179-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-009-9179-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-009-9179-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T23:16:00Z","timestamp":1634771760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-009-9179-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,27]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["9179"],"URL":"https:\/\/doi.org\/10.1007\/s15010-009-9179-z","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,27]]}}}